Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study
Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study have?
Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study has 18 citations in the OpenAlex counts ScholarIQ stores.
When was Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study published?
Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study has 2023 year in the ScholarIQ index.
What is the open-access status of Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study?
Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study has hybrid oa status in the ScholarIQ index.
What is the DOI of Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study?
The DOI for Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study is on the source record.
What is the PMID of Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study?
The PMID for Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study is on the source record.
What is the OpenAlex record for Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study?
The OpenAlex for Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study is on the source record.